A 23-study, 751-patient meta-analysis asks a practical question: when you give neoadjuvant immunotherapy before surgery in resectable head and neck cancer, does adding chemotherapy actually help?
Baratz and colleagues (Mayo Clinic, JAMA Otolaryngology–Head & Neck Surgery, March 2026) pooled the prospective phase 1 and 2 data across three regimens — chemoimmunotherapy, single-agent immunotherapy, and dual-agent immunotherapy — in mostly HPV-negative, locally advanced disease.
What we cover:
- The headline response gap: major-plus-complete pathologic response of 66% with chemoimmunotherapy vs 18% dual-agent vs 6% single-agent
- Complete pathologic response (~38% vs 5% vs 3%) and why radiographic complete responses appeared only in the chemoimmunotherapy arm
- The counterintuitive safety finding — more grade 3–5 events with single-agent immunotherapy (29%) than chemoimmunotherapy (17%) — and why the authors won't draw conclusions from it
- The crucial caveat: these are pooled single-arm trials, not a randomized head-to-head
- Who the likely target population is for a future phase 3 trial: HPV-negative, T3/T4 oral cavity disease
Bottom line: A large, consistent signal that neoadjuvant chemoimmunotherapy outperforms immunotherapy alone on pathologic response — strong enough to justify a phase 3 comparison, not strong enough to settle it.
Source paper Baratz HQ, Hidalgo C, Price DL, et al. Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer: A Systematic Review and Meta-Analysis.
JAMA Otolaryngol Head Neck Surg. Published online March 12, 2026. doi:10.1001/jamaoto.2026.0080
https://doi.org/10.1001/jamaoto.2026.0080 More episodes: hnoncology-journalclub.netlify.app